Prescriptions of GLP-1RAs and SGLT2 inhibitors in type 1 diabetes patients rose from 2010 to 2023, especially among those with elevated cardiorenal risk.
In a recent study published in JAMA Network Open, researchers from the United States of America (US) examined the prescribing trends for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter…
